Home Alzheimer’s Disease Belantamab Mafodotin Triplet Yields Promising Clinical Benefit in Relapsed/Refractory Multiple Myeloma

Belantamab Mafodotin Triplet Yields Promising Clinical Benefit in Relapsed/Refractory Multiple Myeloma

The combination use of belantamab mafodotin plus bortezomib (Velcade) and dexamethasone (B-Vd) induced high clinical benefit rates and a tolerable safety profile in patients with relapsed or refractory multiple myeloma, according to preliminary findings from a cohort of the phase 1/2 DREAMM-6 trial.1

“Preliminary data for the 18 patients who have received belantamab mafodotin 2.5 mg/kg single dosing with bortezomib/dexamethasone suggests that this combination has an acceptable safety profile with no new safety signals identified,” said Ajay K. Nooka, MD, MPH, FACP, associate professor in the Department of Hematology and Medical Oncology, Emory University School of Medicine, in a prerecorded presentation of the early findings for the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. “Clinical response looks promising,” he added.

The objective…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Parasite found in undercooked meat linked with risk of rare brain cancer

submitted by /u/Meat_Mithkabob Continue Reading to the Source

Living up to expectations : braincancer

Hey everyone!I wrote a little something about some of the comments you often hear from others and how sometimes you feel like you need...

My Brain Tumor Taught Me To Shift My Perspective on These 5 Things

submitted by /u/andrewjoegeorge Continue Reading to the Source

Recent Comments